HOME >> BIOLOGY >> NEWS
New hope for patients with chronic lymphocytic leukemia

BUFFALO, NY -- Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) or disease that no longer responds to chemotherapy have experienced a major response to therapy, according to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI). The results are published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study the first to report clinical activity of lenalidomide in patients with CLL 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.


'"/>


4-Dec-2006


Page: 1

Related biology news :

1. Abnormal fat metabolism underlies heart problems in diabetic patients
2. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
3. Aggressive therapy best for certain AML patients
4. Investigating antibiotic use in acute care patients
5. CTRC enrolls first patients in novel phase II study for sarcoma -- living virus destroys cancer cell
6. Co-operation between GSF and clinic improves outlook for sarcoma patients
7. Skin rash actually signifies better outcomes for pancreatic and lung cancer patients
8. Study examines cause of hearing loss for patients with certain genetic disease
9. Stem cell procedure successfully treats amyloidosis patients
10. New research holds promise for protecting cancer patients against infertility
11. Europe struggles to meet the challenges posed by PGD patients travelling abroad

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/27/2019)... (PRWEB) , ... November 26, 2019 , ... ... patients to their Glen Ellyn, IL practice for Invisalign® treatment. Invisalign ... teeth. , Patients with a misaligned bite, also known as malocclusion, present both ...
(Date:11/20/2019)... ... ... BioInformatics Inc., part of Science and Medicine Group, the leading research and advisory ... Science Industry Awards for the most innovative new products in 2019. , Here are ... New Product – Cell Biology, Fluidigm (Gold Award) for ...
(Date:11/19/2019)... ... 19, 2019 , ... Hosted at the Las Vegas Convention Center, and brought ... the largest gathering of MJBiz business professionals in the world. With over 1,300 exhibitors ... there is no show quite like it. Atlantic Ultraviolet will exhibit at Booth C9217, ...
Breaking Biology News(10 mins):
(Date:1/10/2020)... ... January 09, 2020 , ... GenScript Biotech Corp., ... Biotech Global Forum on Jan. 14 in San Francisco, coinciding with the JP ... and the Booming China Market," will feature gene and cell therapy leaders in ...
(Date:1/7/2020)... SOMERVILLE, Mass. (PRWEB) , ... January 06, 2020 ... ... Center for a Digital World at The Fletcher School at Tufts University, is ... P. Sloan Foundation. The grant will be administered by Tufts University, and will ...
(Date:12/30/2019)... ... December 30, 2019 , ... Leak Detection Associates ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries is pleased to announce ... software program specific to the custom-built helium leak testing systems it designs and ...
(Date:12/18/2019)... Pa. (PRWEB) , ... December 17, 2019 , ... ... Nadel LLP is pleased to announce that it has hired Dr. Alia ... pharmaceuticals. , Orbin is experienced in the preparation, filing and prosecution of patent ...
Breaking Biology Technology:
Cached News: